ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2307건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2272 | Active, not recruiting | A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated | Covid19 | Biological: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated Biological: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated Biological: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated Biological: 2 doses of vaccine |
Phase 4 | China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 4400 | All | 3 Years | Yanjin County Center for Disease Control and Prevention, Xinxiang, Henan, China |
| 2271 | Recruiting | A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial | Chronic Fatigue Syndrome | Drug: Fluvoxamine Maleate 100 MG Drug: Placebo Drug: Metformin Extended Release Oral Tablet |
Phase 3 | Cardresearch | OTHER | 1500 | All | 18 Years | CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil City of Brumadinho, Brumadinho, Minas Gerais, Brazil Governador Valadares City Public Health Authority, Governador Valadares, Minas Gerais, Brazil City of Ibirite Public Health Authority, Ibirite, Minas Gerais, Brazil Sociedade Padrao de Educacao Superior, Montes Claros, Minas Gerais, Brazil Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil |
| 2270 | Unknown status | A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19 | COVID-19 | Drug: Favipiravir Other: Placebo |
Phase 3 | Zhejiang Hisun Pharmaceutical Co. Ltd., Opera CRO, a TIGERMED Group Company | INDUSTRY | 256 | All | 18 Years ~ 75 Years | The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Shangcheng District, China Peking University First Hospital, Beijing, Xicheng District, China Department of Internal Medicine Pneumology and infectious diseases Neukolln Clinic, Berlin, Germany Medical clinic and polyclinic IV Hospital of the University of Munich, Munchen, Germany Infectious Diseases Hospital Cluj-Napoca, Cluj-Napoca, Cluj, Romania National Institute of Infectious Diseases "Prof.Dr.Matei Bals", Bucharest, Ilfov, Romania "Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timisoara, Timis, Romania "Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timi?oara, Timis, Romania Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timi?oara, Timis, Romania Emergency County Hospital "Pius Brinzeu"Timisoara, Timi?oara, Timis, Romania |
| 2269 | Completed | A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2) | COVID-19 | Drug: Azithromycin Capsule | Phase 3 | University of Oxford, Pfizer | OTHER | 298 | All | 19 Years | Horton General Hospital, Banbury, Oxfordshire, United Kingdom John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom Ninewells Hospital, Dundee, Scotland, United Kingdom Birmingham City Hospital, Birmingham, United Kingdom Sandwell General Hospital, West Bromwich, United Kingdom |
| 2268 | Recruiting | A Nasal Treatment for COVID-19 | COVID-19 | Drug: Optate Drug: Placebo |
Phase 2 | Indiana University | OTHER | 40 | All | 18 Years ~ 60 Years | Riley Hospital for Children, Indianapolis, Indiana, United States |
| 2267 | Completed | A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab | Relapsing Multiple Sclerosis (RMS) | Drug: Ofatumumab Biological: mRNA COVID-19 vaccine Drug: interferon or glatiramer acetate |
Phase 4 | Novartis Pharmaceuticals | INDUSTRY | 24 | All | 18 Years ~ 55 Years | Center For Neurology and Spine, Phoenix, Arizona, United States Infinity Clinical Research LLC ., Sunrise, Florida, United States Dragonfly Research LLC, Wellesley, Massachusetts, United States Minnesota Center Multiple Sclerosis, Plymouth, Minnesota, United States The MS Center for Innovation in Care, Saint Louis, Missouri, United States The Neurological Institute PA, Charlotte, North Carolina, United States Dayton Center for Neurological Disorders, Centerville, Ohio, United States |
| 2266 | Completed | A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine | COVID-19 | Drug: VXA-CoV2-1.1-S Other: Placebo Tablets |
Phase 2 | Vaxart | INDUSTRY | 66 | All | 18 Years ~ 75 Years | Ark Clinical Research, Long Beach, California, United States AMR Wichita East, Wichita, Kansas, United States Velocity Clinical Research, Inc,, Cleveland, Ohio, United States AMR Knoxville, Knoxville, Tennessee, United States |
